Mosunetuzumab and Polatuzumab Vedotin as First-line Treatment for Large B Cell Lymphoma in Older Unfit or Frail Patients.

Mosunetuzumab combined with polatuzumab vedotin achieved a 61.4% objective response rate as first-line therapy in unfit or frail older patients with diffuse large B-cell lymphoma.

• Why it matters: Older or medically unfit patients often cannot tolerate standard treatments, leaving a critical gap in effective first-line options for this vulnerable population.
• What they did: A multicenter phase I/II trial enrolled 101 patients with a median age of 81, administering six cycles of combined immunotherapy followed by monotherapy, assessing response via PET-CT criteria.
• The result: The treatment showed durable responses with a 56.4% complete response rate, and estimated 2-year survival rates of over 60%, suggesting a promising alternative for carefully selected unfit or frail patients.